NASDAQ:CERE

Cerevel Therapeutics Stock Forecast, Price & News

$12.72

+0.16 (+1.27 %)

(As of 06/24/2021 12:00 AM ET)

Add

Compare

Today's Range

$12.49

▼

$13.00

50-Day Range

$12.56

▼

$15.81

52-Week Range

$9.00

▼

$18.83

Volume310,668 shs

Average Volume242,159 shs

Market Capitalization$1.62 billion

P/E RatioN/A

Dividend YieldN/A

BetaN/A

30 days | 90 days | 365 days | Advanced Chart

Receive CERE News and Ratings via Email

Sign-up to receive the latest news and ratings for Cerevel Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

About Cerevel Therapeutics

Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing CVL-231, a positive allosteric modulator (PAM) that is in Phase Ib clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase II proof-of-concept trials in drug-resistant focal onset seizures in epilepsy or focal onset epilepsy, as well as Phase I proof-of-principle trial for acute anxiety. The company's products also comprise Tavapadon, a selective dopamine D1/D5 partial agonist that is in Phase III clinical trials for the treatment of early- and late-stage Parkinson's disease; CVL-871, a selective dopamine D1/D5 partial agonist for the treatment of dementia-related apathy; and CVL-936, a selective dopamine D3-preferring antagonist, which is in Phase I single ascending dose trials for the treatment of substance use disorder. It is also involved in the development of various preclinical portfolio for various neuroscience indications. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.

Gabrielle Greene-Sulzberger Is The Independent Director of Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) And They Just Picked Up 148% More Shares
June 24, 2021 | finance.yahoo.com

Cerevel Therapeutics (NASDAQ:CERE) Shares Down 4.5%
June 23, 2021 | americanbankingnews.com

Cerevel Therapeutics (NASDAQ:CERE) Shares Gap Down to $13.78
June 22, 2021 | americanbankingnews.com

Morgan Stanley Initiates Coverage On Cerevel Therapeutics Hldg with Overweight Rating, Announces Price Target of $27
June 18, 2021 | benzinga.com

Cerevel Therapeutics shares are trading higher after Morgan Stanley initiated coverage on the stock with an Overweight rating and a $27 price target.
June 18, 2021 | benzinga.com

Cerevel Therapeutics (NASDAQ:CERE) Shares Gap Up to $13.59
June 18, 2021 | americanbankingnews.com

Cerevel Therapeutics (NASDAQ:CERE) Coverage Initiated by Analysts at Morgan Stanley
June 18, 2021 | americanbankingnews.com

Ceres Power: Positive Progress But Still Pricey
June 16, 2021 | seekingalpha.com

Cerevel Gets FDA Fast-Track Designation for CVL-871 in Dementia-Related Apathy
June 15, 2021 | marketwatch.com

Cerevel Therapeutics Announces Fast Track Designation Granted By The FDA To CVL-871 For The Treatment Of Dementia-Related Apathy
June 15, 2021 | benzinga.com

See More Headlines

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryCoal & Consumable Fuels
SectorMedical
Current SymbolNASDAQ:CERE
Previous Symbol
CUSIP15677310
CIK767884
Webceres.net
Phone+1-805-3766500
Employees104
Year FoundedN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book Value$3.02 per share
Price / Book4.21

Profitability

EPS (Most Recent Fiscal Year)($2.01)
Net Income$-152,140,000.00
Net MarginsN/A
Return on Equity-64.65%
Return on Assets-41.11%

Debt

Price-To-Earnings

Miscellaneous

Outstanding Shares127,459,000
Market Cap$1.62 billion
Next Earnings DateN/A
OptionableNot Optionable

MarketRank^™

Overall MarketRank^™

1.95 out of 5 stars

Medical Sector

103rd out of 2,105 stocks

Pharmaceutical Preparations Industry

44th out of 832 stocks

3.4 Analyst's Opinion

Consensus Rating
Cerevel Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $21.50, Cerevel Therapeutics has a forecasted upside of 69.0% from its current price of $12.72.
Amount of Analyst Coverage
Cerevel Therapeutics has only been the subject of 1 research reports in the past 90 days.

3.0 Community Rank

Outperform Votes
Cerevel Therapeutics has received 133 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Cerevel Therapeutics has received 87 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Cerevel Therapeutics has received 60.45% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Cerevel Therapeutics and other stocks. Vote “Outperform” if you believe CERE will outperform the S&P 500 over the long term. Vote “Underperform” if you believe CERE will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Cerevel Therapeutics does not currently pay a dividend.
Dividend Growth
Cerevel Therapeutics does not have a long track record of dividend growth.

3.3 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Cerevel Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $275,357.00 in company stock and sold $0.00 in company stock.
Percentage Held by Institutions
78.49% of the stock of Cerevel Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0 Earnings and Valuation

Earnings Growth
Earnings for Cerevel Therapeutics are expected to decrease in the coming year, from ($1.65) to ($1.73) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Cerevel Therapeutics is -6.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Cerevel Therapeutics is -6.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Cerevel Therapeutics has a P/B Ratio of 4.21. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Cerevel Therapeutics (NASDAQ:CERE) Frequently Asked Questions

Is Cerevel Therapeutics a buy right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cerevel Therapeutics in the last year. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Cerevel Therapeutics stock.
View analyst ratings for Cerevel Therapeutics or view top-rated stocks.

What stocks does MarketBeat like better than Cerevel Therapeutics?

Wall Street analysts have given Cerevel Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Cerevel Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

How were Cerevel Therapeutics' earnings last quarter?

Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) announced its quarterly earnings results on Sunday, May, 16th. The biotechnology company reported ($0.40) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.41) by $0.01.
View Cerevel Therapeutics' earnings history.

What price target have analysts set for CERE?

5 equities research analysts have issued 1-year price targets for Cerevel Therapeutics' stock. Their forecasts range from $17.00 to $27.00. On average, they anticipate Cerevel Therapeutics' stock price to reach $21.50 in the next year. This suggests a possible upside of 69.0% from the stock's current price.
View analysts' price targets for Cerevel Therapeutics or view top-rated stocks among Wall Street analysts.

Who are Cerevel Therapeutics' key executives?

Cerevel Therapeutics' management team includes the following people:

Dr. N. Anthony Coles Jr., CEO & Exec. Chairman (Age 61, Pay $1.24M)
Dr. John J. Renger Ph.D., Chief Scientific Officer (Age 52, Pay $945.08k)
Ms. Kathleen Tregoning M.A., Chief Corp. Affairs Officer (Age 50, Pay $600.79k)
Mr. Abraham N. Ceesay, Pres (Age 43)
Ms. Kathy Y. Yi M.B.A., Chief Financial Officer (Age 49)
Mr. Mark Bodenrader, VP of Fin. & Chief Accounting Officer (Age 48)
Mr. Matthew Calistri, VP of Investor Relations
Mr. Kenneth A. DiPietro, Chief HR Officer (Age 62)
Dr. Ramiro Sanchez, Chief Medical Officer (Age 60)

Who are some of Cerevel Therapeutics' key competitors?

Some companies that are related to Cerevel Therapeutics include CNX Resources (CNX), Warrior Met Coal (HCC), Arch Resources (ARCH), Uranium Energy (UEC), Hallador Energy (HNRG), (URZ) (URZ), Cloud Peak Energy (CLDPQ) and KiOR (KIORQ).
View all of CERE's competitors.

What other stocks do shareholders of Cerevel Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cerevel Therapeutics investors own include Precigen (PGEN), Arena Pharmaceuticals (ARNA), CTI BioPharma (CTIC), Achillion Pharmaceuticals (ACHN), (ANRZQ) (ANRZQ), Cenveo (CVO), Hess (HES), Palatin Technologies (PTN), Aeterna Zentaris (AEZS) and Avid Bioservices (CDMO).

What is Cerevel Therapeutics' stock symbol?

Cerevel Therapeutics trades on the NASDAQ under the ticker symbol "CERE."

Who are Cerevel Therapeutics' major shareholders?

Cerevel Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Perceptive Advisors LLC (3.64%), Price T Rowe Associates Inc. MD (2.67%), Federated Hermes Inc. (1.53%), Ally Bridge Group NY LLC (1.36%), Citadel Advisors LLC (0.96%) and BlackRock Inc. (0.86%).
View institutional ownership trends for Cerevel Therapeutics.

Which institutional investors are selling Cerevel Therapeutics stock?

CERE stock was sold by a variety of institutional investors in the last quarter, including Alyeska Investment Group L.P., Citadel Advisors LLC, Ally Bridge Group NY LLC, Geode Capital Management LLC, Brookfield Asset Management Inc., Morgan Stanley, Penserra Capital Management LLC, and UBS Group AG.
View insider buying and selling activity for Cerevel Therapeutics or view top insider-selling stocks.

Which institutional investors are buying Cerevel Therapeutics stock?

CERE stock was bought by a variety of institutional investors in the last quarter, including Federated Hermes Inc., Bank of New York Mellon Corp, Woodline Partners LP, Millennium Management LLC, Verition Fund Management LLC, Point72 Asset Management L.P., Goldman Sachs Group Inc., and Sphera Funds Management LTD..
View insider buying and selling activity for Cerevel Therapeutics or or view top insider-buying stocks.

How do I buy shares of Cerevel Therapeutics?

Shares of CERE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Cerevel Therapeutics' stock price today?

One share of CERE stock can currently be purchased for approximately $12.72.

How much money does Cerevel Therapeutics make?

Cerevel Therapeutics has a market capitalization of $1.62 billion. The biotechnology company earns $-152,140,000.00 in net income (profit) each year or ($2.01) on an earnings per share basis.

How many employees does Cerevel Therapeutics have?

Cerevel Therapeutics employs 104 workers across the globe.

What is Cerevel Therapeutics' official website?

The official website for Cerevel Therapeutics is ceres.net.

Where are Cerevel Therapeutics' headquarters?

Cerevel Therapeutics is headquartered at 1535 Rancho Conejo Blvd, THOUSAND OAKS, CA 91320-1440, United States.

How can I contact Cerevel Therapeutics?

Cerevel Therapeutics' mailing address is 1535 Rancho Conejo Blvd, THOUSAND OAKS, CA 91320-1440, United States. The biotechnology company can be reached via phone at +1-805-3766500 or via email at [email protected]

This page was last updated on 6/24/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here